

4 Aanonsen LM, Lei SZ, Wilcox GL. Excitatory amino acid receptors and nociceptive neurotransmission in rat spinal cord. *Pain* 1990; 41: 309-21.

5 Aanonsen LM, Wilcox GL. Nociceptive action of excitatory amino acids in the mouse: effects of spinally administered opioids, phencyclidine and sigma agonists. *J Pharmacol Exp Ther* 1987; 243: 9-19.

6 Watkins JC, Evans RH. Excitatory amino acid transmitters. *Annu Rev Pharmacol Toxicol* 1981; 21: 165-204.

7 Song XJ, Zhao ZQ. Differential effects of NMDA and non-NMDA receptors on spinal cutaneous vs muscular nociception in the cat. *Neuroreport* 1993; 4 (1): 17-20.

8 Coderre JJ, Melzack R. The contribution of excitatory amino acid to central sensitization and persistent nociception after formalin-induced tissue injury. *J Neurosci* 1992; 12: 3665-70.

9 Headley PM, Parsons CG, West DC. The role of N-methylaspartate receptors in mediating responses of rat and cat spinal neurones to defined sensory stimuli. *J Physiol (Lond)* 1987; 395: 169-88.

10 Chang HT. Integrative action of thalamus in the process of acupuncture for analgesia. *Sci Sin* 1972; XVI: 47-9.

11 Davies J, Watkins JC. Role of excitatory amino acid receptors in mono- and polysynaptic excitation in the cat spinal cord. *Exp Brain Res* 1983; 49: 280-90.

93,14(6)  
481-485  
NMDA 和非 NMDA 受体介导猫脊髓伤害性和非伤害性信息传递

宋学军, 赵志奇 R 965.2  
(中国科学院上海脑研究所, 上海 200031, 中国)

A 摘要 用多管微电极离子电泳技术研究猫脊髓背角神经元活动。80%的神经元被兴奋性氨基酸 NMDA、使君子氨酸、卡因酸或 DL-高磷丙氨酸 (DLH) 激活。NMDA 受体拮抗剂 APV 和氟胺酮, 非 NMDA 受体拮抗剂 DNQX 以及广谱拮抗剂 4-羟基喹啉酸 (Kyn) 均抑制神经元的伤害性反应。Kyn 抑制非伤害性反应大大强于氟胺酮。NMDA 和非 NMDA 受体均参与介导脊髓伤害性反应, 非伤害性信息主要由非 NMDA 受体介导。

关键词 伤害性感受器; 脊髓; 氨基酸受体; N-甲基-D-门冬氨酸; 使君子氨酸; 卡因酸; DL-高磷丙氨酸

高磷丙氨酸 ~~DLH~~

## Midazolam pharmacokinetics and electroencephalographic changes in eight Chinese men<sup>1</sup>

LU Jian-Feng, WU Mao-Fu, CHEN Gang, XIANG Bing-Ren<sup>2</sup>, AN Deng-Kui<sup>2</sup>  
(Department of Clinical Pharmacy of Jinling Hospital, Nanjing 210002, China; <sup>2</sup>Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China)

ABSTRACT Eight Chinese healthy male volunteers aged  $27 \pm 4$  a were injected iv midazolam (Mid) 15 mg. Blood samples were collected at 0, 2, 5, 7, 10, 20, 30, 45, 60, 90, 120, 180, and 240 min. A HPLC method was established for determining the Mid concentrations in serum. The concentration-time data was fitted with biexponential curve. Pharmacokinetic parameters were:  $T_{1/2\alpha} = 6.8 \pm 2.5$  min,  $T_{1/2\beta} = 118 \pm 27$  min,  $V_c = 25 \pm 7$  L,  $Cl = 393 \pm 79$  ml  $\cdot$  min<sup>-1</sup>,  $V_{dss} = 59 \pm 13$  L,  $AUC_{0-\infty} = 39.6 \pm 8.6$  g  $\cdot$  min  $\cdot$  L<sup>-1</sup>. The

electroencephalogram (EEG) showed a decrease in  $\alpha$  activity and an increase in  $\beta$  activity. The EEG pattern reverted toward baseline after 2-3 h.

Pharmacokinetic and EEG findings suggest that Mid is a preferable anesthesia inducing agent.

KEY WORDS midazolam; pharmacokinetics; high pressure liquid chromatography; electroencephalography

Midazolam (Mid) is used in anesthesia for premedication, induction of anesthesia, and intraoperative hypnosis<sup>[1,2]</sup>. But there has

Received 1992-10-28

Accepted 1993-07-15

<sup>1</sup> Project supported by the Army Eighth Five-year Research Program.

been no report on Mid kinetics in Chinese. Since evaluation of the pharmacokinetic properties of Mid is important for its clinical use, a sensitive HPLC method was established for quantitation of Mid. Pharmacokinetic course of Mid following a single iv dose was studied in 8 Chinese volunteers and EEG changes were observed simultaneously.

**MATERIALS AND METHODS**

**Volunteers** After personal approval and written consent were obtained, 8 healthy men aged  $27 \pm 4$  a, weighing  $61 \pm 4.5$  kg, participated in the study. None was receiving benzodiazepines; all were refrained from alcohol, caffeine-containing beverages and food from the midday prior to the investigation.

**Study design** All studies were undertaken at 4:00 pm in a same room. The subject lay on a bed. Two iv catheters were inserted: One for blood sampling and the other in another arm for injection of Mid. Mid maleate (Roche) 15 mg dissolved in 20 ml of 0.9% saline was injected in 2 min. Wakening was defined as eyes opened and consciousness resumed

**Blood sampling** Venous blood samples (3 ml) were taken at 0, 2, 5, 7, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240 min after infusion was finished. The serum was stored at  $-40^{\circ}\text{C}$ .

**Drug effect measurement** For recording EEG, 5 AgCl electrodes were fixed to scalp. Electrode positions were frontal pole (Fp1, Fp2), occipital (O1, O2) and central zero (C<sub>z</sub>), according to the international 10-20 system. The normal EEG waves and heart beats were recorded on paper 5 min before iv Mid. The EEG and heart beats were simultaneously recorded 10 min after iv and then recored 1 min every 10 min afterwards with a 17-channel EEG instrument (Nihon Kohden 4217) and EEG signals were also recorded in SUN-386 computer for subsequent off-line analysis. The injection time, time of onset of sleep, time of wakening, and respiratory rate were calculated.

**Assay of Mid** Mid concentrations in serum were measured by reverse HPLC<sup>(3,4)</sup>. Serum aliquots of 0.5 ml, to which diazepam was added as internal standard, were mixed with 25  $\mu\text{l}$  NaOH 1 mol  $\cdot$  L<sup>-1</sup> in a centrifuge tube. The sample was extracted with di-

ethylether 8 ml for 1 min with a whirl-mixer and then centrifuged at  $2000 \times g$  for 5 min. Organic phase (5 ml) was evaporated to dryness. The residue was dissolved in methanol 100  $\mu\text{l}$  and 20  $\mu\text{l}$  was injected into a modular Shimadzu HPLC system, consisting of LC-6A pump, SPD-6AV uv detector, C-R6A integrator, and a stainless-steel column (250 mm  $\times$  2 mm) prepacked with ultrasphere TM C18, 3  $\mu\text{m}$ . The uv absorbance detection was set at 220 nm. The mobile phase consisted of methanol-acetonitrile-water (35 : 35 : 30, vol : vol) to which *n*-butylamine 1.2 ml per liter of mobile phase was added. Final pH of the mobile phase was adjusted to 7.0 with HAc and the flow rate was 1 ml  $\cdot$  min<sup>-1</sup>. The retention times of diazepam and Mid were 6.5 and 8.3 min, respectively. The detection limit was approximately 10 ng Mid/ml serum. The CV in this study was <5%.

**Data analysis** The concentration-time data were fitted using weighted ( $1/c^2$ ) least-squares nonlinear regression analysis with the software package PKBP-N1. The pharmacokinetic parameters were calculated for each volunteer using standard equations. EEG tracings before and after iv were compared.

**RESULTS**

The 8 subjects fell asleep at  $58 \pm 13$  s. The time of wakening ranged 106-158 min. The Mid concentration at the time of wakening was  $91 \pm 14$  ng  $\cdot$  ml<sup>-1</sup>.

Heart rate and respiratory rate did not change during or after iv Mid. In all subjects, disappearance of Mid from serum was consistent with the two exponential curve (Fig 1 and Tab 1). The initial distribution half-life of Mid was rapid, with  $T_{1/2\alpha}$  of  $6.8 \pm 2.6$  min. The elimination half life ( $T_{1/2\beta}$ ) was  $118 \pm 27$  min. Mid distribution was reasonably extensive, with  $V_{d\alpha}$  values averaging  $59 \pm 13$  L. Mean total clearance was  $393$  ml  $\cdot$  min<sup>-1</sup>.

The EEG of 8 men were similar. After 60-90 s from the start of 2 min injection,  $\beta$  activity (above 13 Hz) emerged with a decrease of  $\alpha$  activity. The  $\beta$  activity increased rapidly to a maximum 2-5 min from the end of iv, with the disappearance of  $\alpha$  rhythm (8-




Fig 1. Midazolam concentration in serum of 8 men after iv midazolam 15 mg.  $\bar{x} \pm s$ .

13 Hz). Thereafter,  $\beta$  activity declined rapidly. The EEG pattern mainly consisted of  $\beta$  activity with well-modulated spindling. Then the frequency and height of EEG waves decreased gradually. Prior to wakening, some measurable  $\alpha$  rhythm reappeared. The men waked after 2–3 h and EEG pattern reverted to the baseline (Fig 2).

DISCUSSION

The results showed that Mid had only a minor effect on the respiratory and cardiovascular system. All men waked up in 106–158 min which was much longer than the duration reported by Breimer *et al*<sup>(4)</sup>. In a study simi-




Fig 2. EEG tracing (Fp 1) from a man after iv midazolam 15 mg.

lar to ours Breimer *et al* gave 15 mg Mid as a 5-min infusion to 8 young male volunteers weighing  $75 \pm 4$  kg, they found that all volunteers waked up in 60–70 min. The differences of the results might be explained by which method was used. The studies of Breimer *et al* took place in the morning and vigilance was maintained by regular verbal contact. Our study took place in the afternoon and no vigilance was maintained, so the subjects slept longer easily.

Kinetic findings showed that Mid was a short-acting benzodiazepine derivative that was rapidly cleared from plasma. After a quick distribution of  $\alpha$  phase ( $T_{1/2\alpha} = 6.8$  min), elimination of Mid proceeded with a half life averaging 119 min in Chinese men. This was consistent with that reported in similar studies<sup>(1,2,4)</sup>.

Tab 1. Pharmacokinetic parameters for midazolam in individual subjects.

	$\alpha$ min <sup>-1</sup>	$\beta$ min <sup>-1</sup>	$T_{1/2\alpha}$ min	$T_{1/2\beta}$ min	$K_{21}$ min <sup>-1</sup>	$K_{12}$ min <sup>-1</sup>	$K_{10}$ min <sup>-1</sup>	$V_c$ L	$V_{dss}$ L	Cl L · min <sup>-1</sup>	AUC g · min · L <sup>-1</sup>
1	0.079	0.0049	8.8	142	0.033	0.039	0.012	32	70	0.37	40.1
2	0.082	0.0045	8.4	153	0.038	0.039	0.099	31	63	0.30	49.5
3	0.244	0.0049	2.8	141	0.044	0.178	0.027	11	52	0.27	55.2
4	0.138	0.0066	5.0	104	0.048	0.078	0.019	24	55	0.44	34.5
5	0.063	0.0053	11.0	130	0.022	0.031	0.015	33	81	0.52	28.7
6	0.122	0.0097	5.7	71	0.067	0.047	0.018	24	38	0.41	36.8
7	0.099	0.0069	7.0	100	0.041	0.048	0.017	25	53	0.41	36.7
8	0.120	0.0065	5.8	106	0.040	0.066	0.020	22	61	0.42	35.4
$\bar{x}$	0.118	0.0062	6.8	118	0.041	0.066	0.028	25	59	0.39	39.6
s	0.057	0.0017	2.6	27	0.013	0.048	0.029	7	13	0.08	8.6

Clearance was  $393 \text{ ml} \cdot \text{min}^{-1}$  in Chinese men which was similar to what Breimer *et al* reported ( $Cl = 391 \text{ ml} \cdot \text{min}^{-1}$ ). A previous study<sup>[6]</sup> in intensive care patients showed that continuous intravenous infusion had no effect on the value of clearance, which was  $415 \text{ ml} \cdot \text{min}^{-1}$  and similar to the results in healthy volunteers Heizmann *et al* reported<sup>[7]</sup>. So the clearance of Mid did not change easily and there was no difference between Chinese young men and European young men.

Mid tissue distribution was smaller in Chinese men than that in European young men<sup>[4]</sup>. In a study for investigation of the influence of old age and obesity on the kinetics of Mid, Greenblatt *et al* found that the volume in young male volunteers (weighing  $69 \pm 1.7 \text{ kg}$ ) was  $92 \text{ L}$ , and the volume in obesity volunteers was much larger. Furthermore, in intensive care patients received continuous intravenous infusion<sup>[6]</sup>, the volume of Mid increased three times. So the volume of Mid can change with various conditions and there was difference between Chinese men and Europeans.

Sudden administration of benzodiazepines to humans produced a shift in the EEG pattern, usually characterized by increased activity in the  $\beta$  frequency region, ranging from 13 to  $30 \text{ Hz}$ <sup>[6]</sup>. The study considered  $\beta$  activity as the qualitative assessment of central effects of Mid. We found that Mid produced EEG effects of rapid onset. Mid effects were maximal at 2-5 min after the injection. EEG pattern reverted rapidly toward baseline in 2-3 h, i.e., EEG effects became indistinguishable from baseline before plasma concentrations fell to zero. The results were similar to those reported<sup>[5]</sup>. Rapid onset and offset properties may be an important reason to consider Mid to be an anesthetic induction agent preferable to other benzodiazepines.

REFERENCES

- 1 Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. *Br J Clin Pharmacol* 1983; 16: 43s-9s.
- 2 Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. *Anesthesiology* 1984; 61: 27-35.
- 3 Vletter AA, Burm AG, Breimer LT, Spierdijk J. High-performance liquid chromatographic assay to determine midazolam and flumazenil simultaneously in human plasma. *J Chromatogr* 1990; 530: 177-85.
- 4 Breimer LT, Hennis PJ, Burm AG, Danhof M, Bovill JG, Spierdijk J, *et al*. Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers, pharmacokinetic/pharmacodynamic modelling. *Clin Pharmacokinet* 1990; 16: 245-63.
- 5 Koopmans R, Dingemans J, Danhof M, Horsten GP, van Bostel CJ. Pharmacokinetic-pharmacodynamic modeling of midazolam effect on the human central nervous system. *Clin Pharmacol Ther* 1988; 44: 14-22.
- 6 Malacrida R, Fritz ME, Suter PM, Crevoisier C. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. *Crit Care Med* 1992; 20: 1123-6.

485-488

8位健康男性中咪唑安定的药物动力学及脑电图变化

R 971.2

卢建丰, 伍茂福, 陈刚, 相秉仁<sup>1</sup>, 安登魁<sup>1</sup>  
(南京军区总医院药理科, 南京 210002, 中国; <sup>1</sup>中国药科大学药物分析教研室, 南京 210009, 中国)

A

摘要 8位健康男性, iv 咪唑安定 15 mg 后每隔一定时间抽取血样, 咪唑安定浓度用 HPLC 法测定, 血清药物浓度-时间数据用双指数曲线拟合, 主要动力学参数如下:  $T_{1/2\alpha} = 6.8 \pm 2.6 \text{ min}$ ,  $T_{1/2\beta} = 118 \pm 27 \text{ min}$ ,  $V_c = 25 \pm 7 \text{ L}$ ,  $Cl = 393 \pm 79 \text{ ml} \cdot \text{min}^{-1}$ ,  $V_{dss} = 59 \pm 13 \text{ L}$ ,  $AUC_{0-\infty} = 39.6 \pm 8.6 \text{ mg} \cdot \text{min} \cdot \text{L}^{-1}$ . 药后脑电图(EEG)的变化主要为  $\alpha$  波减少,  $\beta$  波明显增多. 药物动力学和 EEG 分析表明咪唑安定是理想的麻醉诱导剂.

药代动力学

关键词 咪唑安定; 药物动力学; 高压液相色谱法; 脑电图